These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8794364)

  • 1. Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet.
    Tachedjian G; Mellors J; Bazmi H; Birch C; Mills J
    J Virol; 1996 Oct; 70(10):7171-81. PubMed ID: 8794364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alkylglycerol prodrugs of phosphonoformate are potent in vitro inhibitors of nucleoside-resistant human immunodeficiency virus type 1 and select for resistance mutations that suppress zidovudine resistance.
    Hammond JL; Koontz DL; Bazmi HZ; Beadle JR; Hostetler SE; Kini GD; Aldern KA; Richman DD; Hostetler KY; Mellors JW
    Antimicrob Agents Chemother; 2001 Jun; 45(6):1621-8. PubMed ID: 11353603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between 3'-azido-3'-deoxythymidine resistance and primer unblocking activity in foscarnet-resistant mutants of human immunodeficiency virus type 1 reverse transcriptase.
    Meyer PR; Matsuura SE; Zonarich D; Chopra RR; Pendarvis E; Bazmi HZ; Mellors JW; Scott WA
    J Virol; 2003 Jun; 77(11):6127-37. PubMed ID: 12743270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
    Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
    J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine.
    García-Lerma JG; MacInnes H; Bennett D; Weinstock H; Heneine W
    J Virol; 2004 Jul; 78(14):7545-52. PubMed ID: 15220429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and in vitro activity of long-chain 5'-O-[(alkoxycarbonyl)phosphinyl]-3'-azido-3'-deoxythymidines against wild-type and AZT- and foscarnet-resistant strains of HIV-1.
    Rosowsky A; Fu H; Pai N; Mellors J; Richman DD; Hostetler KY
    J Med Chem; 1997 Aug; 40(16):2482-90. PubMed ID: 9258355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism by which phosphonoformic acid resistance mutations restore 3'-azido-3'-deoxythymidine (AZT) sensitivity to AZT-resistant HIV-1 reverse transcriptase.
    Arion D; Sluis-Cremer N; Parniak MA
    J Biol Chem; 2000 Mar; 275(13):9251-5. PubMed ID: 10734063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired fitness of foscarnet-resistant strains of human immunodeficiency virus type 1.
    Tachedjian G; Mellors JW; Bazmi H; Mills J
    AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1059-64. PubMed ID: 9718121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
    Mathiesen S; Dam E; Roge B; Joergensen LB; Laursen AL; Gerstoft J; Clavel F
    Antivir Ther; 2007; 12(3):335-43. PubMed ID: 17591023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M; Kemp SD; Parry NR; Larder BA
    Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the Zidovudine Resistance Mutations T215Y, M41L, and L210W in HIV-1 Reverse Transcriptase.
    Boyer PL; Das K; Arnold E; Hughes SH
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7184-96. PubMed ID: 26324274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the Delta67 complex of mutations in human immunodeficiency virus type 1 reverse transcriptase on nucleoside analog excision.
    Boyer PL; Imamichi T; Sarafianos SG; Arnold E; Hughes SH
    J Virol; 2004 Sep; 78(18):9987-97. PubMed ID: 15331732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coresistance to zidovudine and foscarnet is associated with multiple mutations in the human immunodeficiency virus type 1 reverse transcriptase.
    Tachedjian G; French M; Mills J
    Antimicrob Agents Chemother; 1998 Nov; 42(11):3038-43. PubMed ID: 9797252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3'-Azido-3'-deoxythymidine (AZT) and AZT-resistant reverse transcriptase can increase the in vivo mutation rate of human immunodeficiency virus type 1.
    Mansky LM; Bernard LC
    J Virol; 2000 Oct; 74(20):9532-9. PubMed ID: 11000223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and in vitro activities of a new antiviral duplex drug linking Zidovudine (AZT) and Foscarnet (PFA) via an octadecylglycerol residue.
    Schott H; Hamprecht K; Schott S; Schott TC; Schwendener RA
    Bioorg Med Chem; 2009 Jan; 17(1):303-10. PubMed ID: 19010684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations E44D and V118I in the reverse transcriptase of HIV-1 play distinct mechanistic roles in dual resistance to AZT and 3TC.
    Girouard M; Diallo K; Marchand B; McCormick S; Götte M
    J Biol Chem; 2003 Sep; 278(36):34403-10. PubMed ID: 12819190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mutational patterns associated with the 69 insertion complex in multi-drug-resistant HIV-1 reverse transcriptase that confer increased excision activity and high-level resistance to zidovudine.
    Cases-González CE; Franco S; Martínez MA; Menéndez-Arias L
    J Mol Biol; 2007 Jan; 365(2):298-309. PubMed ID: 17070543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro selection of mutations in the human immunodeficiency virus type 1 reverse transcriptase that decrease susceptibility to (-)-beta-D-dioxolane-guanosine and suppress resistance to 3'-azido-3'-deoxythymidine.
    Bazmi HZ; Hammond JL; Cavalcanti SC; Chu CK; Schinazi RF; Mellors JW
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1783-8. PubMed ID: 10858331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphorylation of AZT-resistant human immunodeficiency virus type 1 reverse transcriptase by casein kinase II in vitro: effects on inhibitor sensitivity.
    Lazaro JB; Boretto J; Selmi B; Capony JP; Canard B
    Biochem Biophys Res Commun; 2000 Aug; 275(1):26-32. PubMed ID: 10944435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients.
    Betancor G; Nevot M; Mendieta J; Gómez-Puertas P; Martínez MA; Menéndez-Arias L
    Antiviral Res; 2014 Jun; 106():42-52. PubMed ID: 24667336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.